canin
parvoviru
enter
viru
caus
morbid
mortal
dog
worldwid
sinc
emerg
canin
pathogen
origin
strain
constantli
evolv
primari
variant
cocircul
vari
extent
canin
popul
worldwid
thu
rapid
accur
laboratori
diagnos
variant
crucial
monitor
evolut
convent
method
genotyp
labori
time
consum
determin
genotyp
variant
often
requir
two
reaction
tube
present
studi
develop
probebas
fluoresc
melt
curv
analysi
fmca
genotyp
six
differ
variant
origin
vaccin
strain
cpvpf
cpvint
singl
reaction
tube
use
two
taqman
probe
one
taqman
probe
fam
label
design
perfectli
match
target
sequenc
probe
allow
mismatch
hybrid
gene
region
mismatch
hybrid
anoth
taqman
probe
hex
label
produc
perfectli
match
target
sequenc
origin
probe
enabl
mismatch
hybrid
variant
use
two
taqman
probe
six
variant
readili
distinguish
respect
melt
temperatur
valu
singl
reaction
tube
detect
limit
assay
copi
per
reaction
six
construct
plasmid
cross
reaction
observ
sever
common
canin
virus
assay
coinfect
sampl
also
directli
identifi
via
probebas
fmca
without
use
mix
control
pure
control
requir
clinic
evalu
assay
demonstr
analyz
clinic
fecal
sampl
among
sampl
found
posit
respect
concord
rate
probebas
fmca
sanger
sequenc
thu
duplex
fmca
effect
rapid
simpl
highthroughput
straightforward
genotyp
variant
use
effect
diagnos
monitor
epidemiolog
canin
parvoviru
type
first
identifi
caus
acut
gastroenter
leukopenia
dog
new
antigen
variant
complet
replac
origin
identifi
viru
addit
antigen
variant
identifi
parrish
et
al
buonavoglia
et
al
respect
novel
antigen
variant
still
identifi
includ
new
new
ohshima
et
al
ikeda
et
al
today
variant
origin
identifi
found
vaccin
strain
primari
determin
genotyp
codon
protein
decaro
et
al
b
c
yoon
et
al
decaro
buonavoglia
bingga
et
al
control
diseas
live
modifi
vaccin
wide
use
despit
infect
remain
major
problem
pet
decaro
buonavoglia
furthermor
live
vaccin
may
replic
gastrointestin
tract
shed
along
fece
vaccin
dog
gizzi
et
al
suspect
interfer
diagnost
test
clinic
sign
acut
gastroenter
variant
emerg
vaccin
appear
provid
rel
lower
shorter
immun
heterolog
cpv
decaro
et
al
zhang
et
al
observ
lead
diagnost
dilemma
pup
administ
vaccin
recent
present
clinic
sign
acut
gastroenter
decaro
et
al
base
find
variant
need
identifi
effect
diagnosi
epidemiolog
monitor
sever
approach
employ
type
base
serolog
assay
hemagglutinin
inhibit
hi
test
use
monoclon
antibodi
nakamura
et
al
molecular
method
like
multiplex
amplif
refractori
mutat
system
pcr
armspcr
chander
et
al
minisequenc
base
singlenucleotid
polymorph
snp
analysi
naidu
et
al
pavana
jyothi
et
al
peptid
nucleic
acidbas
pna
array
multiplex
tandem
pcr
mtpcr
meggiolaro
et
al
probe
base
minor
bind
groov
assay
mbg
assay
decaro
et
al
b
c
high
resolut
melt
curv
analysi
hrm
sequenc
analysi
howev
hi
test
need
least
four
monoclon
antibodi
nakamura
et
al
identifi
variant
molecular
method
need
least
two
reaction
decaro
et
al
b
c
et
al
naidu
et
al
bingga
et
al
chander
et
al
pavana
jyothi
et
al
orand
two
technolog
naidu
et
al
bingga
et
al
pavana
jyothi
et
al
meggiolaro
et
al
sequenc
analysi
regard
gold
standard
genotyp
still
time
consum
labor
intens
previou
studi
pcr
coupl
high
resolut
melt
hrm
curv
analysi
develop
genotyp
variant
bingga
et
al
hrm
simpl
rapid
inexpens
method
genotyp
howev
feasibl
detect
multipl
mutat
site
variant
singl
test
tube
use
dna
bind
dye
addit
due
small
melt
temperatur
differ
c
genotyp
variant
perform
gener
heteroduplex
hrm
analysi
bingga
et
al
probebas
fluoresc
melt
curv
analysi
fmca
howev
could
overcom
limit
mention
probebas
fmca
power
tool
snp
genotyp
target
sequenc
base
melt
temperatur
gener
thermal
denatur
probetarget
hybrid
el
housni
et
al
huang
et
al
probebas
fmca
method
larg
rang
melt
temperatur
differ
c
caus
one
two
snp
use
differ
fluoresc
channel
possibl
detect
significantli
greater
mutat
site
one
reaction
tube
el
housni
et
al
huang
et
al
liu
et
al
thu
increas
discriminatori
power
come
melt
temperatur
genotyp
variant
probebas
fmca
method
develop
detect
mutant
sequenc
studi
total
fecal
sampl
fecal
sampl
known
genotyp
collect
field
sampl
collect
four
batch
vaccin
six
plasmid
two
refer
four
control
plasmid
use
studi
supplementari
tabl
plasmid
synthes
base
gene
cpvb
origin
genbank
access
five
plasmid
pcpvpf
pcpvint
gener
use
vector
clone
kit
takara
dalian
china
insert
fragment
plasmid
amplifi
genbank
access
cpvpf
yoon
et
al
three
set
primer
two
duallabel
probe
design
target
gene
use
studi
tabl
primer
set
probe
design
differenti
vaccin
strain
cpvpf
cpvint
origin
figur
tabl
design
perfectli
match
target
sequenc
origin
perfect
match
figur
primer
set
use
origin
gener
recombin
plasmid
use
determin
limit
detect
lod
assay
coinfect
analysi
also
use
sequenc
gene
primer
probe
sequenc
analyz
use
blast
confirm
specif
duplex
fmca
assay
perform
lightcycl
r
realtim
system
roch
switzerland
reaction
contain
taq
plu
master
mix
vazym
nanj
china
primer
primer
primer
primer
abrev
probe
probe
dna
templat
amplif
start
denatur
min
c
follow
amplif
use
cycl
c
c
c
melt
curv
analysi
initi
denatur
c
follow
hybrid
c
stepwis
temperatur
increment
c
ramp
rate
cs
durat
fluoresc
fam
hex
channel
measur
step
melt
curv
analysi
melt
curv
obtain
plot
neg
deriv
fluoresc
intens
respect
temperatur
versu
temperatur
tm
valu
probe
automat
obtain
identifi
peak
correspond
melt
curv
melt
tm
differ
tm
refer
plasmid
detect
sampl
calcul
hex
channel
refer
plasmid
fam
channel
studi
analyt
sensit
duplex
fmca
assay
six
plasmid
pcpvpf
pcpvint
serial
dilut
water
concentr
limit
detect
genotyp
determin
lowest
concentr
measur
duplex
fmca
assay
evalu
reproduc
assay
duplex
fmca
perform
differ
day
use
six
plasmid
known
genotyp
fecal
sampl
canin
distemp
viru
cdv
canin
adenoviru
type
canin
corona
viru
ccv
canin
rotaviru
crv
canin
parainfluenza
viru
cpiv
six
plasmid
use
studi
specif
duplex
fmca
assay
studi
abil
duplex
fmca
assay
distinguish
two
genotyp
present
simultan
sampl
two
six
plasmid
pcpvpf
pcpvint
artifici
poll
variou
ratio
provid
overal
templat
concentr
copi
per
reaction
detect
use
duplex
fmca
assay
total
field
sampl
assess
use
antigen
test
kit
bio
note
south
korea
supplementari
tabl
analyz
use
duplex
fmca
assay
confirm
use
hrm
sequenc
describ
previous
bingga
et
al
studi
known
genotyp
thirti
fecal
sampl
two
vaccin
sampl
use
establish
method
result
show
develop
duplex
fmca
assay
use
duallabel
selfquench
probe
could
identifi
origin
vaccin
strain
cpvpf
cpvint
base
tm
valu
type
fluoresc
melt
peak
shown
figur
c
sampl
two
tm
valu
obtain
hex
fam
channel
correspond
probe
respect
hex
channel
strain
cluster
togeth
tm
valu
c
c
c
respect
origin
cpvpf
strain
cluster
togeth
tm
valu
c
c
respect
two
cluster
easili
differenti
tm
valu
channel
vaccin
strain
cpvint
also
readili
distinguish
strain
base
broader
melt
peak
shape
figur
fam
channel
strain
separ
tm
valu
c
c
c
respect
origin
cpvpf
strain
also
separ
tm
valu
c
c
respect
channel
although
vaccin
strain
cpvpf
yield
tm
valu
c
c
higher
tm
differ
c
hex
channel
thu
obvious
feasibl
distinguish
differ
cpv
strain
base
tm
differ
melt
curv
shape
hex
fam
channel
serial
dilut
six
recombin
plasmid
pcpvpf
pcpvint
rang
test
use
duplex
fmca
assay
fluoresc
signal
correspond
melt
peak
obtain
copi
per
reaction
plasmid
except
copi
per
reaction
supplementari
figur
therefor
detect
limit
duplex
fmca
assay
determin
copi
per
reaction
recombin
plasmid
pcpvpf
pcpvint
copi
per
reaction
specif
duplex
fmca
valid
use
dna
cdna
complementari
dna
sampl
six
variant
five
virus
supplementari
figur
specif
melt
peak
detect
nontarget
dog
virus
cdv
ccv
crv
cpiv
either
fam
hex
channel
result
suggest
design
primer
set
probe
highli
select
specif
target
virus
exhibit
crossreact
sever
common
canin
virus
next
evalu
runtorun
reproduc
duplex
fmca
assay
consid
narrow
tm
window
assay
run
differ
day
use
known
genotyp
fecal
sampl
posit
plasmid
pcpvpf
pcpvint
result
show
sd
absolut
valu
tm
test
sampl
determin
probe
rang
c
tabl
lower
c
result
demonstr
discriminatori
power
develop
method
could
ensur
high
reproduc
tm
valu
assess
capac
fmca
detect
coinfect
unequ
mixtur
two
differ
construct
plasmid
mix
ratio
rang
vv
vari
two
six
plasmid
rel
ratio
result
show
low
one
genotyp
presenc
genotyp
distinguish
mix
sampl
templat
concentr
copi
per
reaction
rel
height
melt
peak
posit
correl
ratio
mix
genotyp
supplementari
figur
consid
almost
imposs
two
kind
vaccin
present
field
sampl
assay
evalu
pcpvpf
pcpvint
simultan
present
reaction
evalu
differenti
power
probebas
fmca
coinfect
field
sampl
strain
identifi
contain
use
hrm
assay
dna
sequenc
previou
studi
bingga
et
al
detect
use
probebas
fmca
result
show
coinfect
sampl
could
easili
identifi
use
probebas
fmca
assay
figur
present
studi
three
batch
vanguard
r
plu
vaccin
batch
one
batch
nobivac
r
dhppi
vaccin
batch
also
detect
use
duplex
fmca
assay
result
show
batch
nobivac
r
dhppi
vaccin
contain
one
strain
cpvint
howev
three
batch
vanguard
r
plu
vaccin
includ
origin
cpvpf
strain
simultan
figur
confirm
result
dna
sequenc
bingga
et
al
carri
detect
strain
present
three
batch
vanguard
r
plu
vaccin
sequenc
result
show
vanguard
r
plu
includ
sleev
peak
nt
complet
cpv
genom
sequenc
chromatographi
indic
vaccin
contain
origin
cpvpf
strain
simultan
figur
addit
confirm
result
purifi
pcr
product
three
batch
vanguard
r
plu
also
clone
use
kit
takara
dalian
china
twothreethre
origin
eightsevenseven
cpvpf
detect
ten
random
clone
respect
estim
capabl
probebas
fmca
method
distinguish
field
variant
fecal
sampl
collect
test
use
probebas
fmca
method
supplementari
figur
fecal
sampl
posit
posit
posit
remain
sampl
neg
supplementari
tabl
dna
sequenc
fecal
sampl
confirm
novel
develop
method
could
distinguish
differ
strain
accuraci
supplementari
tabl
melt
curv
analysi
conjunct
realtim
pcr
includ
highresolut
melt
curv
analysi
hrm
montgomeri
et
al
er
chang
bruzzon
steer
taqman
probebas
fmca
el
housni
et
al
wide
use
clinic
laboratori
detect
snp
compar
taqman
probebas
fmca
hrm
simpl
rapid
inexpens
method
snp
test
laboratori
pcr
coupl
hrm
curv
analysi
also
develop
genotyp
canin
parvoviru
type
variant
bingga
et
al
howev
hrm
analysi
encount
technic
difficulti
differ
genotyp
one
sampl
need
detect
simultan
singl
reaction
tube
problem
solv
use
probebas
fmca
advantag
probebas
fmca
abil
multiplex
detect
use
probe
specif
melt
temperatur
templat
dna
fulli
match
probe
sequenc
probe
bind
specif
melt
temperatur
templat
dna
mismatch
probe
melt
temperatur
decreas
remark
compar
match
hybrid
thu
tm
differ
tm
fulli
match
hybrid
mismatch
hybrid
allow
research
detect
snp
variat
singl
reaction
tube
studi
two
taqman
probe
design
identifi
six
differ
variant
use
melt
temperatur
differ
singl
tube
taqman
probe
typic
dual
label
hydrolysi
probe
standard
taqman
probe
consist
bp
oligonucleotid
probe
label
report
fluorophor
end
quencher
fluorophor
end
livak
et
al
solut
randomli
coil
conform
enabl
fluoresc
quench
quencher
fluorophor
remain
proxim
thu
nonhybrid
taqman
probe
weakli
fluoresc
probe
hybrid
target
strong
fluoresc
occur
quencher
fluorophor
separ
length
probe
denatur
probetarget
hybrid
probe
return
weakli
fluoresc
randomli
coil
conform
studi
famlabel
taqman
probe
establish
perfectli
match
target
sequenc
probe
allow
mismatch
hybrid
gene
region
mismatch
hybrid
result
fmca
show
melt
temperatur
differ
tm
fulli
match
hybrid
mismatch
hybrid
c
c
mismatch
hybrid
respect
therefor
tm
valu
suffici
classifi
three
melt
temperatur
clearli
singl
detect
experi
howev
one
limit
use
famlabel
probe
assay
could
discrimin
origin
strain
similar
nucleic
acid
target
sequenc
figur
thu
hexlabel
taqman
probe
produc
distinguish
origin
strain
base
melt
temperatur
differ
hexlabel
taqman
probe
design
perfectli
match
target
sequenc
origin
strain
variant
mismatch
mismatch
hybrid
result
tm
c
origin
addit
two
attenu
live
vaccin
strain
cpvpf
cpvint
also
success
identifi
use
two
taqman
probe
mutat
correspond
target
sequenc
figur
notabl
mismatch
hybrid
caus
chang
melt
temperatur
howev
melt
temperatur
also
affect
mismatch
posit
taqman
probe
studi
strain
vaccin
strain
cpvpf
mismatch
hybrid
famlabel
taqman
probe
mismatch
posit
differ
valu
probe
melt
temperatur
howev
c
c
cpvpf
respect
p
phenomenon
also
occur
hexlabel
probe
probe
melt
temperatur
c
c
cpvint
respect
p
may
caus
differ
nearestneighbor
base
next
mismatch
site
affect
tm
probe
santalucia
assay
sequenc
analysi
execut
parallel
field
sampl
result
show
accuraci
achiev
probebas
fmca
method
accuraci
achiev
hrm
assay
supplementari
tabl
increas
accuraci
fmca
deriv
larger
tm
differ
hrm
differ
genotyp
exampl
melt
temperatur
shift
c
use
probebas
fmca
significantli
higher
tm
differ
c
hrm
analysi
previou
studi
hrm
analysi
discrimin
addit
hybrid
step
gener
heteroduplex
bingga
et
al
moreov
distinguish
cpv
genotyp
includ
two
vaccin
strain
accomplish
use
four
separ
reaction
tube
hrm
assay
bingga
et
al
done
singl
reaction
tube
two
label
probe
fmca
previous
coinfect
differ
variant
report
sporad
dog
eg
coinfect
clinic
case
battilani
et
al
perez
et
al
bingga
et
al
vaccin
decaro
et
al
laboratori
coinfect
sampl
contain
detect
hrm
analysi
previou
studi
bingga
et
al
present
studi
two
strain
mix
sampl
readili
distinguish
use
probebas
fmca
method
comparison
hrm
method
coinfect
sampl
directli
identifi
probebas
fmca
without
use
mix
control
pure
control
requir
figur
mix
sampl
contain
heteroduplex
homoduplex
speci
pcr
melt
curv
coinfect
sampl
combin
melt
profil
montgomeri
et
al
hrm
assay
higher
melt
temperatur
peak
combin
two
homoduplex
melt
profil
lower
melt
temperatur
peak
also
combin
two
heteroduplex
melt
profil
probebas
fmca
howev
higher
melt
temperatur
peak
deriv
one
duplex
melt
profil
perfectli
match
probe
lower
melt
temperatur
peak
deriv
one
duplex
melt
profil
mismatch
probe
thu
compon
mix
sampl
detect
label
probe
directli
four
duplex
probebas
fmca
assay
howev
feasibl
identifi
ingredi
coinfect
sampl
use
intercal
dyesbas
hrm
assay
without
use
mix
control
notabl
develop
probebas
fmca
assay
use
detect
commerci
attenu
live
vaccin
vanguard
r
plu
two
melt
peak
observ
fam
channel
accord
tm
valu
vaccin
contain
cpvpf
c
origin
c
simultan
height
melt
peak
indic
cpvpf
domin
sequenc
result
pcr
product
clone
experi
confirm
two
differ
strain
cpvpf
origin
coexist
commerci
vaccin
vanguard
r
plu
thu
develop
method
also
use
tool
rapid
identif
vaccin
puriti
point
probebas
bicolor
fmca
assay
develop
studi
design
accord
snp
codon
abl
identifi
domin
type
includ
origin
vaccin
strain
cpvpf
cpvint
figur
codon
like
determin
antigen
variant
new
decaro
et
al
decaro
buonavoglia
due
classic
variant
almost
replac
new
sporad
case
occur
supplementari
figur
develop
probebas
fmca
differenti
new
variant
type
howev
classic
orand
preval
tricolor
probebas
fmca
base
codon
develop
solv
problem
conclus
studi
describ
first
time
simpl
rapid
accur
highthroughput
straightforward
method
genotyp
strain
includ
origin
vaccin
strain
cpvpf
cpvint
use
duplex
probebas
fmca
develop
method
also
use
detect
coinfect
sampl
directli
without
sequenc
dataset
gener
studi
found
ncbi
ethic
approv
need
studi
committe
ethic
anim
experi
institut
anim
health
guangdong
academi
agricultur
scienc
accord
constitut
ethic
anim
experi
institut
anim
health
guangdong
academi
agricultur
scienc
guidelin
institut
zl
gb
conceiv
studi
wrote
manuscript
cz
carri
data
analysi
jj
collect
detect
field
sampl
use
antigen
test
kit
hs
jy
particip
manuscript
prepar
zl
gb
cz
jz
design
experi
author
read
approv
final
manuscript
